Call Options

15 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$8.9 - $14.11 $707,550 - $1.12 Million
79,500 Added 15.07%
606,900 $6.07 Million
Q2 2024

Aug 15, 2024

SELL
$11.96 - $15.71 $2.17 Million - $2.85 Million
-181,200 Reduced 25.57%
527,400 $6.33 Million
Q1 2024

May 07, 2024

BUY
$11.35 - $16.73 $3.99 Million - $5.88 Million
351,500 Added 98.43%
708,600 $10.5 Million
Q4 2023

Feb 14, 2024

SELL
$5.77 - $12.19 $332,352 - $702,144
-57,600 Reduced 13.89%
357,100 $4.3 Million
Q3 2023

Nov 14, 2023

BUY
$6.27 - $8.15 $1.42 Million - $1.84 Million
225,900 Added 119.65%
414,700 $2.63 Million
Q2 2023

Aug 11, 2023

SELL
$6.63 - $9.9 $118,014 - $176,220
-17,800 Reduced 8.62%
188,800 $1.48 Million
Q1 2023

May 16, 2023

BUY
$5.72 - $7.91 $255,684 - $353,577
44,700 Added 27.61%
206,600 $1.43 Million
Q4 2022

Feb 14, 2023

SELL
$4.68 - $6.54 $1.5 Million - $2.09 Million
-320,300 Reduced 66.42%
161,900 $1.03 Million
Q3 2022

Nov 14, 2022

BUY
$3.73 - $8.39 $1.51 Million - $3.39 Million
404,500 Added 520.59%
482,200 $2.62 Million
Q2 2022

Aug 15, 2022

BUY
$3.37 - $7.55 $119,972 - $268,780
35,600 Added 84.56%
77,700 $339,000
Q1 2022

May 16, 2022

BUY
$5.14 - $7.38 $121,303 - $174,168
23,600 Added 127.57%
42,100 $302,000
Q3 2021

Nov 15, 2021

SELL
$2.28 - $2.95 $34,656 - $44,840
-15,200 Reduced 45.1%
18,500 $51,000
Q2 2021

Aug 11, 2021

SELL
$2.51 - $3.11 $95,128 - $117,869
-37,900 Reduced 52.93%
33,700 $96,000
Q1 2021

May 17, 2021

BUY
$2.42 - $3.6 $37,994 - $56,520
15,700 Added 28.09%
71,600 $193,000
Q4 2020

Feb 16, 2021

BUY
$2.6 - $5.79 $145,340 - $323,661
55,900 New
55,900 $165,000

Others Institutions Holding LQDA

About Liquidia Corp


  • Ticker LQDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,362,300
  • Market Cap $632M
  • Description
  • Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...
More about LQDA
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.